Levocabastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H29FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H68BP06S81, chemically known as 4-piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, (3s-(1(cis),3alpha,4beta))- but generally known as levocabastine, which bears US NIH Compound Identifier 54385. European Medicines Agency schedules Levocabastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08465MIG. The term LEVOCABASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). World Health Organization schedules levocabastine in its Anatomical Therapeutic Chemical (ATC) Classification. LEVOCABASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule levocabastine under HS 29333999 and SITC 51574. As of Q4 2014, LEVOCABASTINE remains the US FDA Preferred Term for this commodity. Levocabastine bears US NLM identifiers UMLS ID C0064870 and NCI Concept Code C61806. SMILES: FC1CCC(C2(CCC(N3CC(C(CC3)(C3CCCCC3)C(=O)O)C)CC2)C#N)CC1.